To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP; To evaluate the treatment pattern in metastatic NSCLC patients after QIP.
The primary objective of this study is to assess the implementation of standardized diagnosis and treatment practice in oncology departments of Small/Middle tier cities and County hospitals, after standardized education and implementation of lung cancer clinical practice guidelines for oncology physicians.
Study Type
OBSERVATIONAL
Enrollment
1,000
Research Site
Anning, China
Research Site
Anqing, China
Research Site
Changzhi, China
Research Site
Daqing, China
Research Site
Dazhou, China
Research Site
Dazhu, China
To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP
Molecular testing-rate for the first-line treatment: Defined as the number of participants received molecular testing for the first-line treatment divided by total participants.
Time frame: Approximately 1 month after last patient in
To evaluate the treatment pattern in metastatic NSCLC patients after QIP
TKIs first-line treatment rate: Defined as TKIs first-line treatment rate in AGA positive participants.
Time frame: Approximately 1 month after last patient in
To evaluate the clinical outcomes in metastatic NSCLC patients after QIP
Progression Free Survival (PFS): Defined as the time from beginning of first-line treatment to disease progression or death for any cause, whichever occurs first.
Time frame: Follow up approximately 24 months after last patient in
To evaluate the treatment pattern in metastatic NSCLC patients after QIP
1st/2nd/3rd generation EGFR-TKIs first-line treatment rate: Defined 1st/2nd/3rd generation EGFR-TKIs first-line treatment rate in EGFR positive participants.
Time frame: Approximately 1 month after last patient in
To evaluate the treatment pattern in metastatic NSCLC patients after QIP
Immunotherapy first-line treatment rate: Defined as PD-1 or PD-L1 inhibitors first-line treatment rate in AGA negative participants.
Time frame: Approximately 1 month after last patient in
To evaluate the clinical outcomes in metastatic NSCLC patients after QIP
Response rate: Defined as the percentage of participants with the disease first-line treatment response by investigator assessment as recorded in CRF.
Time frame: Follow up approximately 24 months after last patient in
To evaluate the clinical outcomes in metastatic NSCLC patients after QIP
Disease control rate: Defined as the percentage of participants with the disease first-line treatment control by investigator assessment as recorded in CRF
Time frame: Follow up approximately 24 months after last patient in
To evaluate the clinical outcomes in metastatic NSCLC patients after QIP
Duration of Response: Defined as the time from first-line treatment response to disease progression or death in participants who achieve responding by investigator assessment as recorded in CRF.
Time frame: Follow up approximately 24 months after last patient in
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Dingzhou, China
Research Site
Ganzhou, China
Research Site
Guangzhou, China
Research Site
Guang’an, China
...and 36 more locations